<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04601051</url>
  </required_header>
  <id_info>
    <org_study_id>ITL-2001-CL-001</org_study_id>
    <secondary_id>2020-002034-32</secondary_id>
    <nct_id>NCT04601051</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)</brief_title>
  <official_title>Phase 1 Two-Part (Open-label, Single Ascending Dose (Part 1) and Open-label, Single Dose Expansion (Part 2)) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intellia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intellia Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and&#xD;
      pharmacodynamics (PD) of NTLA-2001 in participants with hereditary transthyretin amyloidosis&#xD;
      with polyneuropathy (ATTRv-PN).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 2-part first in human (FIH) study consists of an open-label, single ascending dose Part&#xD;
      1, which may identify the optimal biologically active dose (OBD) of NTLA-2001, followed by&#xD;
      Part 2, if applicable, an open-label, single-dose expansion at the OBD to further&#xD;
      characterize activity of NTLA-2001, provide an initial assessment of the effect of NTLA-2001&#xD;
      on clinical measures of neuropathy and neurologic function, and obtain additional safety data&#xD;
      at the OBD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with Treatment-Emergent Adverse Events</measure>
    <time_frame>up to Day 730 for each dose-escalation cohort in Part 1 and in Part 2 (up to 24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with Clinically Significant Clinical Laboratory Test Findings</measure>
    <time_frame>up to Day 730 for each dose-escalation cohort in Part 1 and in Part 2 (up to 24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with Clinically Significant Safety Measurements</measure>
    <time_frame>up to Day 730 for each dose-escalation cohort in Part 1 and in Part 2 (up to 24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Percent Change from Baseline in Serum TTR (enzyme-linked immunosorbent assay [ELISA])</measure>
    <time_frame>Baseline (Predose); Day 7, Day 14, Day 28, Day 56, Day 112, Day 168, Day 252, Day 365, Day 545, and Day 730 for each dose-escalation cohort in Part 1 and in Part 2 (up to 24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Percent Change from Baseline in Serum Prealbumin</measure>
    <time_frame>Baseline (Predose); Days 14, 28, and 56 for each dose-escalation cohort in Part 1 and in Part 2 (up to 24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Mean Area Under the Plasma Concentration-Time Curve from Time Zero to the Time of the Last Measurable Concentration (AUClast) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA</measure>
    <time_frame>up to Day 730</time_frame>
    <description>Samples will be collected predose, 30 minutes (min), 60 min, and at end of infusion during the infusion period. Post infusion samples will be collected at 15 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 8 h, 12 h, 24 h (Day 2), and 48 h (Day 4), Day 4, Day 7, Day 14, Day 28, Day 56, Day 112, Day 168, Day 252, Day 365, Day 545, and Day 730.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Mean Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUCinf) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA</measure>
    <time_frame>up to Day 730</time_frame>
    <description>Samples will be collected predose, 30 minutes (min), 60 min, and at end of infusion during the infusion period. Post infusion samples will be collected at 15 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 8 h, 12 h, 24 h (Day 2), and 48 h (Day 4), Day 4, Day 7, Day 14, Day 28, Day 56, Day 112, Day 168, Day 252, Day 365, Day 545, and Day 730.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Mean Maximum Concentration (Cmax) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA</measure>
    <time_frame>up to Day 730</time_frame>
    <description>Samples will be collected predose, 30 minutes (min), 60 min, and at end of infusion during the infusion period. Post infusion samples will be collected at 15 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 8 h, 12 h, 24 h (Day 2), and 48 h (Day 4), Day 4, Day 7, Day 14, Day 28, Day 56, Day 112, Day 168, Day 252, Day 365, Day 545, and Day 730.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Mean Time of the Maximum Concentration (Tmax) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA</measure>
    <time_frame>up to Day 730</time_frame>
    <description>Samples will be collected predose, 30 minutes (min), 60 min, and at end of infusion during the infusion period. Post infusion samples will be collected at 15 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 8 h, 12 h, 24 h (Day 2), and 48 h (Day 4), Day 4, Day 7, Day 14, Day 28, Day 56, Day 112, Day 168, Day 252, Day 365, Day 545, and Day 730.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Mean Terminal Half-Life (t½) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA</measure>
    <time_frame>up to Day 730</time_frame>
    <description>Samples will be collected predose, 30 minutes (min), 60 min, and at end of infusion during the infusion period. Post infusion samples will be collected at 15 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 8 h, 12 h, 24 h (Day 2), and 48 h (Day 4), Day 4, Day 7, Day 14, Day 28, Day 56, Day 112, Day 168, Day 252, Day 365, Day 545, and Day 730.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Mean Apparent Clearance (CL) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA</measure>
    <time_frame>up to Day 730</time_frame>
    <description>Samples will be collected predose, 30 minutes (min), 60 min, and at end of infusion during the infusion period. Post infusion samples will be collected at 15 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 8 h, 12 h, 24 h (Day 2), and 48 h (Day 4), Day 4, Day 7, Day 14, Day 28, Day 56, Day 112, Day 168, Day 252, Day 365, Day 545, and Day 730.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Mean Volume of Distribution (Vd) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA</measure>
    <time_frame>up to Day 730</time_frame>
    <description>Samples will be collected predose, 30 minutes (min), 60 min, and at end of infusion during the infusion period. Post infusion samples will be collected at 15 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 8 h, 12 h, 24 h (Day 2), and 48 h (Day 4), Day 4, Day 7, Day 14, Day 28, Day 56, Day 112, Day 168, Day 252, Day 365, Day 545, and Day 730.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and 2: Change from Baseline in Anti-Drug Antibody to NTLA-2001 and Anti-Cas9 Protein Antibody to Transgene Product Levels</measure>
    <time_frame>Baseline (Predose); Day 14, Day 28, Day 56, Day 112, Day 168, Day 365, Day 545, and Day 730 for each dose-escalation cohort in Part 1 and in Part 2 (up to 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in Familial Amyloid Polyneuropathy (FAP) Stage</measure>
    <time_frame>Baseline (Predose); Day 168, Day 365, and Day 730 for each dose-escalation cohort in Part 1 and in Part 2 (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in Polyneuropathy Disability (PND) Score</measure>
    <time_frame>Baseline (Predose); Day 168, Day 365, and Day 730 for each dose-escalation cohort in Part 1 and in Part 2 (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in Modified Body Mass Index (mBMI)</measure>
    <time_frame>Baseline (Predose); Day 28, Day 168, Day 365, and Day 730 for each dose-escalation cohort in Part 1 and in Part 2 (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Screening in Neuropathy Impairment Score (NIS)</measure>
    <time_frame>Screening; Day 28, Day 365, and Day 730 for each dose-escalation cohort in Part 1 and in Part 2 (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change from Baseline in Modified Neuropathy Impairment Score +7 (mNIS+7)</measure>
    <time_frame>Baseline (Predose); Day 365 and Day 730 (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Screening in 10-Meter Walk Test (10-MWT)</measure>
    <time_frame>Screening; Day 168, Day 365, and Day 730 for each dose-escalation cohort in Part 1 and in Part 2 (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN)</measure>
    <time_frame>Baseline (Predose); Day 28, Day 168, Day 365, and Day 730 for each dose-escalation cohort in Part 1 and in Part 2 (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Change from Baseline in EuroQOL (EQ)-5D-5L</measure>
    <time_frame>Baseline (Predose); Day 168, Day 365, and Day 730 for each dose-escalation cohort in Part 1 and in Part 2 (up to 24 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Hereditary Transthyretin Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Part 1: NTLA-2001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants, assigned to one of 4 dose-escalation cohorts, will receive a single dose of NTLA-2001 on Day 1 and will then be followed for up to 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: NTLA-2001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the optimal biologically active dose (OBD) of NTLA-2001 identified in Part 1 as a single dose on Day 1 and will then be followed for up to 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NTLA-2001</intervention_name>
    <description>A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration</description>
    <arm_group_label>Part 1: NTLA-2001</arm_group_label>
    <arm_group_label>Part 2: NTLA-2001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and/or female participants 18 to 80 years of age inclusive, at the time of&#xD;
             signing the informed consent&#xD;
&#xD;
          -  Diagnosis of polyneuropathy (PN) due to transthyretin (TTR) amyloidosis (ATTR)&#xD;
&#xD;
          -  Must have a body weight of at least 45 kilograms (kg) at Screening visit&#xD;
&#xD;
          -  Lack of access to approved treatments for ATTR and/or progression of hereditary&#xD;
             transthyretin amyloidosis with polyneuropathy (ATTRv-PN) despite use of approved&#xD;
             treatment for ATTRv-PN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Amyloidosis attributable to non-TTR protein, e.g., amyloid light-chain (AL) amyloidosis&#xD;
&#xD;
        • Known leptomeningeal transthyretin amyloidosis&#xD;
&#xD;
        • Use of any of the following TTR-directed therapy for ATTR within the specified timeframe:&#xD;
&#xD;
          1. Patisiran (small interfering ribonucleic acid [siRNA] therapeutic formulated LNP):&#xD;
&#xD;
               -  Part 1: prior history of use,&#xD;
&#xD;
               -  Part 2: last dose administered less than 90 days prior to study drug&#xD;
                  administration.&#xD;
&#xD;
          2. Inotersen (antisense oligonucleotide [ASO)]):&#xD;
&#xD;
               -  Part 1: prior history of use,&#xD;
&#xD;
               -  Part 2: last dose administered less than 160 days prior to study drug&#xD;
                  administration,&#xD;
&#xD;
          3. Vutrisiran (investigational siRNA therapeutic GalNAc conjugate): prior history of use,&#xD;
&#xD;
          4. Tafamidis (TTR stabilizer): participant must be on stable dose for a minimum of 14&#xD;
             days,&#xD;
&#xD;
          5. Diflunisal (TTR stabilizer): last dose administered less than 3 days prior to study&#xD;
             drug dosing,&#xD;
&#xD;
          6. Doxycycline and/or tauroursodeoxycholic acid (TTR matrix solvent): last dose&#xD;
             administered less than 14 days of study drug dosing,&#xD;
&#xD;
          7. Any other investigational agent for the treatment of ATTRv-PN: last dose administered&#xD;
             less than 30 days or 5 half-lives, whichever is longer, prior to study drug dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trial Manager at Intellia</last_name>
    <phone>833-888-0387</phone>
    <email>clinicalscience@intelliatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Umea</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NTLA-2001</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Neurologic Function</keyword>
  <keyword>Clustered Regularly Interspaced Short Palindromic Repeats</keyword>
  <keyword>CRISPR</keyword>
  <keyword>Polyneuropathy</keyword>
  <keyword>ATTR</keyword>
  <keyword>Transthyretin</keyword>
  <keyword>TTR</keyword>
  <keyword>Amyloidosis</keyword>
  <keyword>Familial Amyloid Polyneuropathy</keyword>
  <keyword>FAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Amyloid Neuropathies, Familial</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

